Treatment of adult soft tissue sarcoma: Old concepts, new insights, and potential for drug discovery

Cancer Investigation

Volumn 30, Issue 4, 2012, Pages 300-308

  Aragon Ching, Jeanny B ^a   Maki, Robert G ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Soft tissue sarcoma; Targeted agents

Indexed keywords

CEDIRANIB; CELECOXIB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; INTERLEUKIN 2; NAVELBINE; NILOTINIB; PACLITAXEL; RAPAMYCIN; SOMATOMEDIN; SORAFENIB; STEM CELL FACTOR RECEPTOR; SULINDAC; SUNITINIB; T LYMPHOCYTE RECEPTOR; TAMOXIFEN; TOREMIFENE; TRABECTEDIN; UNINDEXED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ALVEOLAR SOFT PART SARCOMA; ANGIOGENESIS; ANGIOSARCOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL SARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; DESMOPLASTIC SMALL ROUND CELL TUMOR; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; FIBROSIS; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GIANT CELL TUMOR; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; META ANALYSIS (TOPIC); MYXOSARCOMA; NATIONAL HEALTH ORGANIZATION; OSTEOCLASTOMA; PERIVASCULAR EPITHELIOID CELL TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PIGMENTED VILLONODULAR SYNOVITIS; PLASMA CELL GRANULOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; WOUND COMPLICATION;

ADULT; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASM STAGING; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84860162681     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.658936     Document Type: Article

References (88)

1. Collini P, Sorensen PH, Patel S, Blay JY, Issels RD, Maki RG, Eriksson M, del Muro XG. Sarcomas with spindle cell morphology. Semin Oncol 2009; 36(4):324-337.
2. Wagner A. Treatment of advanced sof tissue sarcoma: conventional agents and promising new drugs. J Natl Compr Canc Netw 2007; 5(4):401-410. (Pubitemid 46713829)
3. Canter RJ, Qin LX, Ferrone CR, Maki RG, Singer S, Brennan MF. Why do patients with low-grade sof tissue sarcoma die? Ann Surg Oncol 2008; 15(12):3550-3560.
4. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of sof tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984; 53(3):530-541. (Pubitemid 14182732)
5. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, Sastre X, Vilain MO, Bonichon F, N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult sof tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91(10):1914-1926. (Pubitemid 32424119)
6. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the beneft of adjuvant radiation therapy in the treatment of sof tissue sarcomas of the extremity. J Clin Oncol 1998; 16(1):197-203. (Pubitemid 28041599)
7. Davis AM, O'Sullivan B, Bell RS, Turcotte R, Catton CN, Wun-der JS, Chabot P, Hammond A, Benk V, Isler M, Freeman C, Goddard K, Bezjak A, Kandel RA, Sadura A, Day A, James K, Tu D, Pater J, Zee B. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity sof tissue sarcoma. J Clin Oncol 2002; 20(22):4472-4477. (Pubitemid 35334759)
8. Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CD, Singer S. Long-term outcomes afer function-sparing surgery without radiotherapy for sof tissue sarcoma of the extremities and trunk. J Clin Oncol 1999; 17(10):3252-3259. (Pubitemid 29470660)
9. Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant radiation for stage II-B sof tissue sarcoma of the extremity. J Clin Oncol 2002; 20(6):1643-1650. (Pubitemid 34260546)
10. Adjuvant chemotherapy for localised resectable sof-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350(9092):1647-1654.
11. Adjuvant chemotherapy for localised resectable sof tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst Rev 2000;(2):CD001419.
12. Adjuvant chemotherapy for localised resectable sof tissue sarcoma in adults. Cochrane Database Syst Rev 2000;(4):CD001419.
13. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable sof-tissue sarcoma. Cancer 2008; 113(3):573-581.
14. Frustaci S, Berretta M, Comandone A, Bidoli E, De Paoli A, Gherlinzoni F, De Pas T, Barbieri E, Pertici M, Apice G, Picci P. Adjuvant treatment of high-risk adult sof tissue sarcomas: a survey by the Italian Sarcoma Group. Tumori 2006; 92(2):92-97. (Pubitemid 43835966)
15. Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, Boz G, Gherlinzoni F. Ifosfamide in the adjuvant therapy of sof tissue sarcomas. Oncology 2003; 65 Suppl 2:80-84. (Pubitemid 37346738)
16. Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofbrosarcoma of the extremity. Cancer 2011.
17. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist 2007; 12(8):999-1006. (Pubitemid 47359143)
18. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Tall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic sof tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25(19):2755-2763. (Pubitemid 47123184)
19. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes difer-entiation in myxoid liposarcoma tumors. Mol Cancer Ter 2009; 8(2):449-457.
20. Blay JY, von Mehren M, Samuels BL, Fanucchi MP, Ray-Coquard I, Buckley B, Gilles L, Lebedinsky C, Elsayed YA, Le Cesne A. Phase I combination study of trabectedin and doxorubicin in patients with sof-tissue sarcoma. Clin Cancer Res 2008; 14(20):6656-6662.
21. von Mehren M. Trabectedin-a targeted chemotherapy? Lancet Oncol 2007; 8(7):565-567.
22. Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz-Gurpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Tomas DM. Other targetable sarcomas. Semin Oncol 2009; 36(4):358-371.
23. Italiano A, Cardot N, Dupre F, Monticelli I, Keslair F, Piche M, Mainguene C, Coindre JM, Pedeutour F. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the "missing link" between lipomas and liposarcomas? Int J Cancer 2007; 121(2):308-315. (Pubitemid 46917699)
24. O'Cearbhaill R, Hensley ML. Optimal management of uterine leiomyosarcoma. Expert Rev Anticancer Ter 2010; 10(2):153-169.
25. Pautier P, Bui Nguyen B, Penel P, Piperno-Neumann S, Delcambre-Lair C, Bompas E, Collin F, Rey A, Jimenez M, Duffaud F. Final results of a FNCLCC French Sarcoma Group multi-center randomized phase II study of gemcitabine (G) versus gem-citabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol 2009; 25(15):abstr 10527.
26. Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced sof tissue sarcomas: results of a phase II trial. Cancer 2007; 109(9):1863-1869. (Pubitemid 46668552)
27. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M, Brodin B. Cancer/testis antigen expression in human mes-enchymal stem cells: downregulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 2005; 65(6):2207-2215. (Pubitemid 40490129)
28. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Rafeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29(7):917-924.
29. Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay JY, Hohenberger P. Testing new regimens in patients with advanced sof tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2010.
30. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26(32):5269-5274.
31. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005; 11(3):241-247. (Pubitemid 44698813)
32. Breiteneder-Gelef S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D. Angiosarcomas express mixed endothelial phe-notypes of blood and lymphatic capillaries: podoplanin as a specifc marker for lymphatic endothelium. Am J Pathol 1999; 154(2):385-394. (Pubitemid 29094089)
33. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol 2010; 11(10):983-991.
34. Ryan CW, Mehren Mv, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC. Phase II intergroup study of sorafenib (S) in advanced sof tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008; 26(S):Abstr 10532.
35. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraf AS, Elias AD, Brockstein B, Blachere NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27(19):3133-3140.
36. Agulnik M, Okuno SH, Mehren MV, Jovanovic B, Brockstein B, Benjamin RS, Evens AM. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma J Clin Oncol 2009; 27(15S):Abstr 10522.
37. Pastore G, Peris-Bonet R, Carli M, Martinez-Garcia C, Sanchez de Toledo J, Steliarova-Foucher E. Childhood sof tissue sarcomas incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42(13):2136-2149.
38. Pappo AS, Shapiro DN, Crist WM. Rhabdomyosarcoma. Biology and treatment. Pediatr Clin North Am 1997; 44(4):953-972.
39. Qualman SJ, Cofn CM, Newton WA, Hojo H, Triche TJ, Parham DM, Crist WM. Intergroup Rhabdomyosarcoma Study: update for pathologists. Pediatr Dev Pathol 1998; 1(6):550-561. (Pubitemid 128542175)
40. Blakely ML, Lobe TE, Anderson JR, Donaldson SS, Andrassy RJ, Parham DM, Wharam MD, Qualman SJ, Wiener ES, Grier HE, Crist WM. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg 1999; 34(5):736-741; discussion 741-732.
41. Williamson D, Missiaglia E, de Reynies A, Pierron G, Tuille B, Palenzuela G, Tway K, Orbach D, Lae M, Freneaux P, Pritchard-Jones K, Oberlin O, Shipley J, Delattre O. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28(13):2151-2158.
42. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, Bridge JA, Crist WM, Triche TJ, Barr FG. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J Clin Oncol 2002; 20(11):2672-2679. (Pubitemid 34575640)
43. Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosar-coma: a report from the Sof Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer 2004; 42(1):64-73. (Pubitemid 38173459)
44. Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Intergroup rhabdomyosar-coma study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001; 19(12):3091-3102. (Pubitemid 32567502)
45. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, Heyn R, Lawrence W, Newton W, Ortega J, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 1988; 61(2):209-220. (Pubitemid 18056471)
46. Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES, Crist WM. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Trough IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma 2001; 5(1):9-15. (Pubitemid 32319864)
47. Walterhouse D, Watson A. Optimal management strategies for rhabdomyosarcoma in children. Paediatr Drugs 2007; 9(6):391-400. (Pubitemid 350208913)
48. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, et al. The Tird Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13(3):610-630.
49. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhab-domyosarcoma: children's oncology group study D9803. J Clin Oncol 2009; 27(31):5182-5188.
50. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001; 23(5):272-276. (Pubitemid 32662033)
51. Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993; 71(5):1904-1922. (Pubitemid 23067412)
52. Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A. The dermatofbrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59(15):3719-3723. (Pubitemid 29381878)
53. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH. Growth inhibition of dermatofbrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61(15):5778-5783. (Pubitemid 32769094)
54. McArthur G. Dermatofbrosarcoma protuberans: recent clinical progress. Ann Surg Oncol 2007; 14(10):2876-2886. (Pubitemid 47460644)
55. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM. Ima-tinib mesylate in advanced dermatofbrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28(10):1772-1779.
56. West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, Zhu S, Marinelli RJ, De Luca A, Downs-Kelly E, Goldblum JR, Corless CL, Brown PO, Gilks CB, Nielsen TO, Huntsman D, van de Rijn M. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translo-cation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103(3):690-695. (Pubitemid 43153087)
57. Blay JY, El Sayadi H, Tiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19(4):821-822. (Pubitemid 351461057)
58. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28(5):835-840.
59. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fbromatoses (desmoid tumors). Am J Pathol 1997; 151(2):329-334. (Pubitemid 27330053)
60. Davies DR, Armstrong JG, Takker N, Horner K, Guy SP, Clancy T, Sloan P, Blair V, Dodd C, Warnes TW, et al. Severe Gardner syndrome in families with mutations restricted to a specifc region of the APC gene. Am J Hum Genet 1995; 57(5):1151-1158.
61. Couture J, Mitri A, Lagace R, Smits R, Berk T, Bouchard HL, Fodde R, Alman B, Bapat B. A germline mutation at the extreme 3' end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of beta-catenin in the desmoid tumor. Clin Genet 2000; 57(3):205-212. (Pubitemid 30168748)
62. Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D. Specifc mutations inthe beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173(5):1518-1527.
63. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as frst-line treatment for desmoid tumors. Cancer 2004; 100(3):612-620. (Pubitemid 38128287)
64. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pen-nacchioli E, Dileo P, Rasponi A, Ferrari A, Pilotti S, Casali PG. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fbromatosis. Cancer 2001; 92(5):1259-1264.
65. Chao AS, Lai CH, Hsueh S, Chen CS, Yang YC, Soong YK. Successful treatment of recurrent pelvic desmoid tumour with tamox-ifen: case report. Hum Reprod 2000; 15(2):311-313. (Pubitemid 30076709)
66. Benson JR, Mokbel K, Baum M. Management of desmoid tumours including a case report of toremifene. Ann Oncol 1994; 5(2):173-177. (Pubitemid 24062573)
67. Leithner A, Schnack B, Katterschafa T, Wiltschke C, Amann G, Windhager R, Kotz R, Zielinski CC. Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin. J Surg Oncol 2000; 73(1):21-25. (Pubitemid 30067529)
68. Gounder M, Lefowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG. Activity of sorafenib against desmoid tumor/deep fbromatoses. Clin Cancer Res 2011.
69. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer 1993; 72(11):3244-3247. (Pubitemid 23356767)
70. de Camargo VP, Keohan ML, D'Adamo DR, Antonescu CR, Brennan MF, Singer S, Ahn LS, Maki RG. Clinical outcomes of systemic therapy for patients with deep fbromatosis (desmoid tumor). Cancer 2010; 116(9):2258-2265.
71. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efcacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7):472-480. (Pubitemid 34879334)
72. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joen-suu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl 2:S1-29; quiz S30.
73. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikof JA, Tan BR, Owzar K. Adjuvant imatinib mesylate afer resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373(9669):1097-1104.
74. Joensuu H, Eriksson M, Hatrmann J, Sundby Hall K, Schutte J, Re-ichardt A, Schlemmer M, Wardelmann E, Ramadori G, Al-Batran S, Nilsson BE, Monge O, Kallio R, Sarlomo-Rikala M, Bono P, Leinonen M, Hohenberger P, Alvegard T, Reichardt P. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 2011; 29:Abstr LBA1.
75. Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2010; 67 Suppl 1:S25-43.
76. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010; 28(33):4985-4995.
77. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351(9113):1393-1396. (Pubitemid 28209997)
78. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94(14):1099-1106. (Pubitemid 34830730)
79. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001; 11(5):289-297. (Pubitemid 34257726)
80. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007; 12(8):1007-1018. (Pubitemid 47359144)
81. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograf growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006; 8(5):394-401. (Pubitemid 43830746)
82. Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of os-teosarcoma. Cancer Res 2005; 65(6):2406-2411. (Pubitemid 40490152)
83. Chawla SP, Tolcher AW, Staddon AP, Schuetze S, D'Amato GZ, Blay JY, Loewy J, Kan R, Demetri GD. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced sof tissue or bone sarcomas: Update of phase II trial. J Clin Oncol 2007; 25(18S):Abstr 10076.
84. Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui Nguyen B, Cranmer LD, Reichardt P, Bompas E, Song Y, Lee R, Eid JE, Loewy J, Haluska FG, Dodion PF, Demetri GD. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical beneft from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011; 29:abstr 10005.
85. Stacchiotti S, Negri T, Zafaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S. Sunitinib in advanced alveolar sof part sarcoma: evidence of a direct antitumor effect. Ann Oncol 2011; 22(7):1682-1690.
86. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303(5659):844-848.
87. Ray-Coquard IL, Blay J, Italiano A, Cesne AL, Penel N, Zhi J, Bery-ozkina A, Heil F, Rueger R, Nichols GL, Nguyen BB. Neoadjuvant MDM2 antagonist RG7112 for well-diferentiated and dedifer-entiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study. J Clin Oncol 2011; 29(S):Abstr 10007b.
88. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Janne PA, Maki RG, Demetri GD, Shapiro GI. Crizotinib in ALK-rearranged infammatory myofbroblastic tumor. N Engl J Med 2010; 363(18):1727-1733.